|
1
|
Levallet G, Bergot E, Antoine M, Creveuil
C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet
J, Morin F, et al Intergroupe Francophone de Cancérologie
Thoracique (IFCT), : High TUBB3 expression, an independent
prognostic marker in patients with early non-small cell lung cancer
treated by preoperative chemotherapy, is regulated by K-Ras
signaling pathway. Mol Cancer Ther. 11:1203–1213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shao M, Jin B, Niu Y, Ye J, Lu D and Han
B: Association of POLK polymorphisms with platinum-based
chemotherapy response and severe toxicity in non-small cell lung
cancer patients. Cell Biochem Biophys. 70:1227–1237. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsch FR, Herbst RS, Olsen C, Chansky K,
Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M and
Gandara DR: Increased EGFR gene copy number detected by fluorescent
in situ hybridization predicts outcome in non-small-cell lung
cancer patients treated with cetuximab and chemotherapy. J Clin
Oncol. 26:3351–3357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Z, Xiao Y, Zhao J, Chen M, Xu Y,
Zhong W, Xing J and Wang M: Relationship between circulating tumour
cell count and prognosis following chemotherapy in patients with
advanced non-small-cell lung cancer. Respirology. 21:519–525. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsumoto M, Nakajima W, Seike M, Gemma A
and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung
cancer cells is dependent on Bax- and Bak-induction pathway and
synergistically activated by BH3-mimetic ABT-263 in p53 wild-type
and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cui J, Mo J, Luo M, Yu Q, Zhou S, Li T,
Zhang Y and Luo W: c-Myc-activated long non-coding RNA H19
downregulates miR-107 and promotes cell cycle progression of
non-small cell lung cancer. Int J Clin Exp Pathol. 8:12400–12409.
2015.PubMed/NCBI
|
|
9
|
Yi Y, Lu X, Chen J, Jiao C, Zhong J, Song
Z, Yu X and Lin B: Downregulated miR-486-5p acts as a tumor
suppressor in esophageal squamous cell carcinoma. Exp Ther Med.
12:3411–3416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo J, Li H and Zhang C: MicroRNA-7
inhibits the malignant phenotypes of non-small cell lung cancer in
vitro by targeting Pax6. Mol Med Rep. 12:5443–5448. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Qian J, Qiang Y, Huang H, Wang C,
Li D and Xu B: Down-regulation of miR-4500 promoted non-small cell
lung cancer growth. Cell Physiol Biochem. 34:1166–1174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao M, Gao FH, Wang JY, Liu F, Yuan HH,
Zhang WY and Jiang B: JAK2/STAT3 signaling pathway activation
mediates tumor angiogenesis by upregulation of VEGF and bFGF in
non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guerriero I, D'Angelo D, Pallante P,
Santos M, Scrima M, Malanga D, De Marco C, Ravo M, Weisz A,
Laudanna C, et al: Analysis of miRNA profiles identified miR-196a
as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer
cells. Oncotarget. 8:19172–19191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang J, Feng X, Zhou W, Wu Y and Yang Y:
MiR-128 reverses the gefitinib resistance of the lung cancer stem
cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget.
7:73188–73199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang Y, Zhang C, Wu T, Wang Q, Liu J and
Dai P: Transcriptome sequencing reveals key pathways and genes
associated with cisplatin resistance in lung adenocarcinoma A549
Cells. PLoS One. 12:e01706092017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Checinska A, Hoogeland BS, Rodriguez JA,
Giaccone G and Kruyt FA: Role of XIAP in inhibiting
cisplatin-induced caspase activation in non-small cell lung cancer
cells: A small molecule Smac mimic sensitizes for
chemotherapy-induced apoptosis by enhancing caspase-3 activation.
Exp Cell Res. 313:1215–1224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ueda K, Kawashima H, Ohtani S, Deng WG,
Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, et al:
The 3p21.3 tumor suppressor NPRL2 plays an important role in
cisplatin-induced resistance in human non-small-cell lung cancer
cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang C, Chen YX, Wu NY, Yin JY, Li XP,
Huang HS, Zhang W, Zhou HH and Liu ZQ: MiR-488 inhibits
proliferation and cisplatin sensibility in non-small-cell lung
cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling
pathway. Sci Rep. 7:403842017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Zhang Y, He J, Fu Y, Lin C and Li
X: MicroRNA-133b is regulated by TAp63 while no gene mutation is
present in colorectal cancer. Oncol Rep. 37:1646–1652. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Lan T, Zhang W, Dong L, Kang N,
Zhang S, Fu M, Liu B, Liu K and Zhan Q: Feed-forward reciprocal
activation of PAFR and STAT3 regulates epithelial-mesenchymal
transition in non-small cell lung cancer. Cancer Res. 75:4198–4210.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao D, Pan C, Sun J, Gilbert C,
Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D,
et al: VEGF drives cancer-initiating stem cells through
VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene.
34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen
Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes
cisplatin resistance in non-small-cell lung cancer NSCLC.
Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou W, Bi X, Gao G and Sun L: miRNA-133b
and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling
pathway in human renal carcinoma cells. Biomed Pharmacother.
84:722–729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Q, Yue J, Zhang C, Gu X, Chen H and
Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses
epithelial-mesenchymal transition (EMT) and suppresses migration
and invasion in non-small cell lung cancer (NSCLC). Oncotarget.
6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X,
Peng L, Sun J and Chen Z: miR-223 reverses the resistance of
EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol.
48:1855–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu Z, Liu D, Fan C, Luan L, Zhang X and
Wang E: DIXDC1 increases the invasion and migration ability of
non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway. Mol
Carcinog. 53:917–925. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sin TK, Wang F, Meng F, Wong SC, Cho WC,
Siu PM, Chan LW and Yung BY: Implications of microRNAs in the
treatment of gefitinib-resistant non-small cell lung cancer. Int J
Mol Sci. 17:2372016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Q, Liang X, Dai J and Guan X:
Prostaglandin transporter, SLCO2A1, mediates the invasion and
apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. Int J
Clin Exp Pathol. 8:9175–9181. 2015.PubMed/NCBI
|
